Biological therapy of chronic rhinosinusitis
Authors:
Balatková Z. 1; Knížek Z. 2; J. Vodička 2
; Plzák J. 1
Authors‘ workplace:
Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN v Motole, Praha
1; Klinika otorinolaryngologie a chirurgie hlavy a krku FZS UP a Nemocnice Pardubického kraje, a. s., Pardubická nemocnice
2
Published in:
Otorinolaryngol Foniatr, 70, 2021, No. 2, pp. 109-114.
Category:
Review Article
doi:
https://doi.org/10.48095/ccorl2021109
Overview
The aim of this paper is to present an up-to-date information about therapeutical options in chronic rhinosinusitis with nasal polyps. First choice therapy is a long term regular application of intranasal steroids in combination with salinic solution douches. If this treatment is not eff ective enough, then the pulses of systemic steroids are indicated. If the sufficient control of the disease is not achieved, then surgery is a therapeutic choice; it means functional endoscopic sinus surgery in the extent corresponding to the extension of the sinus disease. However, there remains a certain group of patients in whom the results with this treatment are not optimal. The type 2 immunopathological response affects relevantly the course of the disease. Nowadays, the research is done in this field. Specific agents, which are able to block circulating inflammatory mediators or bind receptors for these mediators are developed and studied. The results of the studies having been completed by now are promising.
Keywords:
biological therapy – chronic rhinosinusitis – nasal polyps – dupilumab – immunoglobulin E – interleukin
Sources
1. Fokkens WJ, Lund VJ, Hopkins C et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58(Suppl S29): 1–464. Doi: 10.4193/ Rhin20. 600.
2. De Greve G, Hellings PW, Fokkens WJ et al. Endotype- driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017; 7: 22. Doi: 10.1186/ s13601-017-0157-8.
3. Gandhi NA, Bennett BL, Graham NM et al. Targeting key proximal drivers of type 2 infl ammation in disease. Nat Rev Drug Discov 2016; 15(1): 35–50. Doi: 10.1038/ nrd4624.
4. Hirose K, Iwata A, Tamachi T et al. Allergic air way infl ammation: key players beyond the Th2 cell pathway. Immunol Rev 2017; 278(1): 145–161. Doi: 10.1111/ imr.12540.
5. Khan A, Vandeplas G, Huynh TMT et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019; 57(1): 32–42. Doi: 10.4193/ Rhin17.255.
6. Pundir V, Pundir J, Lancaster G et al. Role of corticosteroids in Functional Endoscopic Sinus Surgery--a systematic review and meta- -analysis. Rhinology 2016; 54(1): 3–19. Doi: 10.4193/ Rhin15.079.
7. Fokkens WJ, Lund V, Bachert C et al. EUFOREA consensus on bio logics for CRSwNP with or without asthma. Allergy 2019; 74(12): 2312–2319. Doi: 10.1111/ all.13875.
8. Gevaert P, Calus L, Van Zele T et al. Omalizumab is eff ective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131(1): 110–116 e111. Doi: 10.1016/ j.jaci.2012.07.047.
9. Tsetsos N, Goudakos JK, Daskalakis D et al. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology 2018; 56(1): 11– 21. Doi: 10.4193/ Rhin17.156.
10. Krug N, Hohlfeld JM, Kirsten AM et al. Allergen- induced asthmatic responses modified by a GATA3-specifi c DNAzyme. N Engl J Med 2015; 372(21): 1987–1995. Doi: 10.1056/ NEJMoa 1411776.
11. Panousis C, Dhagat U, Edwards KM et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors. MAbs 2016; 8(3): 436–453. Doi: 10.1080/ 19420862.2015.1119352.
12. Lan F, Zhang N, Holtappels G et al. Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell-derived Cytokines. Am J Respir Crit Care Med 2018; 198(4): 452–463. Doi: 10.1164/ rccm.201710-2112OC.
13. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993; 31(4): 183–184.
14. Pinto JM, Mehta N, DiTineo M et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010; 48(3): 318–324. Doi: 10.4193/ Rhin09.144.
15. Oblitas CM, Galeano-Valle F, Vela-De La Cruz L et al. Omalizumab as a provoking factor for venous thromboembolism. Drug Target Insights 2019; 13: 1177392819861987. Doi: 10.1177/ 1177392819861987.
16. Bachert C, Sousa AR, Lund VJ et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol 2017; 140(4): 1024–1031 e1014. Doi: 10.1016/ j.jaci.2017.05.044.
17. Gevaert P, Van Bruaene N, Cattaert T et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128(5): 989–995. Doi: 10.1016/ j.jaci.2011.07.056.
18. Bachert C, Mannent L, Naclerio RM et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016; 315(5): 469–479. Doi: 10.1001/ jama.2015.19330.
19. Jonstam K, Swanson BN, Mannent LP et al. Dupilumab reduces local type 2 pro-infl ammatory bio markers in chronic rhinosinusitis with nasal polyposis. Allergy 2019; 74(4): 743–752. Doi: 10.1111/ all.13685.
20. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol 2015; 136(6): 1431–1440. Doi: 10.1016/ j.jaci.2015.10.010.
21. Toma S, Hopkins C. Stratifi cation of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments. Rhinology 2016; 54(2): 129–133. Doi: 10.4193/ Rhin15.072.
22. Doty RL, Frye RE, Agrawal U. Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identifi cation Test. Percept Psychophys 1989; 45(5): 381–384. Doi: 10.3758/ bf03210709.
23. Bachert C, Han JK, Desrosiers M et al. Effi - cacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS- 52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel- -group phase 3 trials. Lancet 2019; 394(10209): 1638–1650. Doi: 10.1016/ S0140-6736(19)31881-1.
24. Iino Y, Sekine Y, Yoshida S et al. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma. Auris Nasus Larynx 2020. Doi: 10.1016/ j. anl.2020.09.001.
25. Pierchalla G, Fluhr JW, Förster-Ruhrmann U et al. Pilot study: Clinical eff ects of dupilumab therapy on eosinophilic otitis media in patients with severe nasal polyposis. Laryngorhinootologie 2020; 99(S 02): S39. Doi: 10.1055/ s-0040- 1710838.
26. Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 2020; 16: 31–37. Doi: 10.2147/ TCRM.S210648.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2021 Issue 2
Most read in this issue
- Biological therapy of chronic rhinosinusitis
- Grisel’s syndrome – case report
- Surgical treatment of benign parotid gland tumors in the years 2014–2018 at the ENT department of Hospital České Budějovice, a.s.
- Neuromonitoring of the recurrent laryngeal nerve in thyroid gland surgery – results and experiences